Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma.

ABSTRACT:

Background

Malignant peritoneal mesothelioma (MPM) is an extremely rare and highly invasive tumor. Due to the lack of accurate models that reflect the biological characteristics of primary tumors, studying MPM remains challenging and is associated with an exceedingly unfavorable prognosis. This study was aimed to establish a new potential preclinical model for MPM using patient-derived MPM organoids (MPMOs) and to comprehensively evaluate the practicality of this model in medical research and its feasibility in guiding individualized patient treatment.

Methods

MPMOs were constructed using tumor tissue from MPM patients. Histopathological analysis and whole genome sequencing (WGS) were employed to determine the ability of MPMOs to replicate the original tumor's genetic and hi

SUBMITTER: Fang X 

PROVIDER: S-EPMC10782772 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature